Q2 2026 13F · SEC CIK 1977548
Checkpoint Capital L.P.
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $389.8M
- Reported positions
- 6
- Top holdings a year, 3 yrs
- +35.6%
- Assets under management
- $333.8M
Checkpoint Capital L.P. is a hedge fund that reported 6 positions worth $389.8M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Rhythm Pharmaceuticals Inc (RYTM, 33.8%), Argenx SE (ARGNF, 31.3%), Revolution Medicines Inc (RVMD, 19.7%). A portfolio copying its top holdings returned 35.6% a year over the last 3 years, against 18.8% for the S&P 500.
Checkpoint Capital L.P. holdings all 6 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| RYTMRhythm Pharmaceuticals Inc | 33.8% | -3.4% | $131.7M |
| ARGNFArgenx SE | 31.3% | -14.2% | $121.8M |
| RVMDRevolution Medicines Inc | 19.7% | +56.3% | $76.9M |
| CYTKCytokinetics | 10.4% | +163.9% | $40.5M |
| IRONDisc Medicine Inc | 4.5% | -16.2% | $17.6M |
| TRVITrevi Therapeutics Inc | 0.4% | +50.0% | $1.4M |
What Checkpoint Capital L.P. bought and sold in Q2 2026, against Q1 2026.
New positions
No new positions among the largest holdings.
Added to
- CYTK Cytokinetics+163.9% shares
- RVMD Revolution Medicines Inc+56.3% shares
- TRVI Trevi Therapeutics Inc+50.0% shares
Reduced
- IRON Disc Medicine Inc-16.2% shares
- ARGNF Argenx SE-14.2% shares
Sold out
- SEPN Septerna Incwas 0.9%
- CRNX Crinetics Pharmaceuticals inwas 0.5%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +61.7% /yr
- S&P 500 +20.1%
- 3 years
- +35.6% /yr
- S&P 500 +18.8%
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $389.8M | 6 |
| Q1 2026 | $278.7M | 8 |
| Q4 2025 | $315.6M | 6 |
| Q3 2025 | $298.5M | 10 |
| Q2 2025 | $214.6M | 8 |
| Q1 2025 | $182.3M | 14 |
| Q4 2024 | $196.5M | 16 |
| Q3 2024 | $201.6M | 16 |
| Q2 2024 | $165.9M | 16 |
| Q1 2024 | $149.6M | 17 |
| Q4 2023 | $143.3M | 17 |
Questions about Checkpoint Capital L.P.'s portfolio
What stocks does Checkpoint Capital L.P. own?
Checkpoint Capital L.P.'s latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 6 positions worth $389.8M. The largest are Rhythm Pharmaceuticals Inc (RYTM) at 33.8%, Argenx SE (ARGNF) at 31.3%, Revolution Medicines Inc (RVMD) at 19.7%, Cytokinetics (CYTK) at 10.4% and Disc Medicine Inc (IRON) at 4.5%.
What did Checkpoint Capital L.P. buy last quarter?
In Q2 2026, Checkpoint Capital L.P. added Cytokinetics (CYTK) (+163.9% shares), Revolution Medicines Inc (RVMD) (+56.3% shares) and Trevi Therapeutics Inc (TRVI) (+50.0% shares), compared with its Q1 2026 filing.
What did Checkpoint Capital L.P. sell last quarter?
In Q2 2026, Checkpoint Capital L.P. sold all of Septerna Inc (SEPN), sold all of Crinetics Pharmaceuticals in (CRNX), Disc Medicine Inc (IRON) (-16.2% shares) and Argenx SE (ARGNF) (-14.2% shares), compared with its Q1 2026 filing.
How has Checkpoint Capital L.P.'s portfolio performed?
A portfolio copying Checkpoint Capital L.P.'s 20 largest 13F holdings each quarter, from the day each filing was public, returned +35.6% a year over the last 3 years, against +18.8% for the S&P 500. Over 1 year: +61.7% against +20.1%.
When is Checkpoint Capital L.P.'s next 13F filing due?
13F filings are due 45 days after each quarter ends. Checkpoint Capital L.P.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Checkpoint Capital L.P. manage?
Checkpoint Capital L.P. reported $333.8M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $389.8M.